These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 25155376)
1. Fascin and EMMPRIN expression in primary mucinous tumors of ovary: a tissue microarray study. Alici O; Kefeli M; Yildiz L; Baris S; Karagoz F; Kandemir B Pathol Res Pract; 2014 Dec; 210(12):934-8. PubMed ID: 25155376 [TBL] [Abstract][Full Text] [Related]
2. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Cao D; Ji H; Ronnett BM Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919 [TBL] [Abstract][Full Text] [Related]
3. Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Jin JS; Yao CW; Loh SH; Cheng MF; Hsieh DS; Bai CY Int J Gynecol Pathol; 2006 Apr; 25(2):140-6. PubMed ID: 16633062 [TBL] [Abstract][Full Text] [Related]
4. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy. Wen YH; Yee H; Goswami S; Shukla PS Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814 [TBL] [Abstract][Full Text] [Related]
5. Expression profile of mucins in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors. Wang J; El-Bahrawy MA Int J Gynecol Pathol; 2014 Mar; 33(2):166-75. PubMed ID: 24487472 [TBL] [Abstract][Full Text] [Related]
6. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms. McCluggage WG J Clin Pathol; 2012 Jul; 65(7):596-600. PubMed ID: 21768188 [TBL] [Abstract][Full Text] [Related]
9. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. Tsai WC; Sheu LF; Nieh S; Yu CP; Sun GH; Lin YF; Chen A; Jin JS World J Urol; 2007 Mar; 25(1):73-80. PubMed ID: 17021824 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining. Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987 [TBL] [Abstract][Full Text] [Related]
11. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic. Perez Montiel D; Arispe Angulo K; Cantú-de León D; Bornstein Quevedo L; Chanona Vilchis J; Herrera Montalvo L Ann Diagn Pathol; 2015 Aug; 19(4):249-52. PubMed ID: 26059401 [TBL] [Abstract][Full Text] [Related]
12. [Expression of fascin and CK14 in different histological types of cancer and its differential diagnostic significance]. Xue LY; Zou SM; Zheng S; Xie YQ; Wen P; Liu XY; Lin DM; Lü N Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):838-44. PubMed ID: 21223690 [TBL] [Abstract][Full Text] [Related]
13. The role of actin bundling protein fascin in the progression of ovarian neoplasms. Kabukcuoglu S; Oner U; Ozalp SS; Bildirici K; Yalcin OT; Colak E Eur J Gynaecol Oncol; 2006; 27(2):171-6. PubMed ID: 16620064 [TBL] [Abstract][Full Text] [Related]
14. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039 [TBL] [Abstract][Full Text] [Related]
15. Clinical factors and biomarkers in ovarian tumors development. Vrabie CD; Petrescu A; Waller M; Dina I Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637 [TBL] [Abstract][Full Text] [Related]
16. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms. Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616 [TBL] [Abstract][Full Text] [Related]
17. Diversity in size and signal intensity in multilocular cystic ovarian masses: new parameters for distinguishing metastatic from primary mucinous ovarian neoplasms. Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Saida T; Yoshikawa H; Minami M J Magn Reson Imaging; 2013 Oct; 38(4):794-801. PubMed ID: 23440747 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478 [TBL] [Abstract][Full Text] [Related]
19. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Ronnett BM; Shmookler BM; Sugarbaker PH; Kurman RJ Anat Pathol; 1997; 2():197-226. PubMed ID: 9575376 [TBL] [Abstract][Full Text] [Related]
20. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]